View Older Stories View More Recent Stories
-
Moderna & Merck Announce 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated Sustained Improvement in the Primary Endpoint of Recurrence-Free Survival in P
-
Moderna (MRNA) call put ratio 4.4 calls to 1 put with a focus on January calls as share price up 6.8%
-
RBC Capital on Moderna (MRNA): 'we remain cautious on MRNA's ability to break even in 2028'
-
Moderna raises 2025 revenue forecast to $1.9 billion
-
Moderna Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference
-
Moderna (MRNA) call put ratio 1.2 calls to 1 put into the annual J.P. Morgan Healthcare Conference
-
UBS Assumes Moderna (MRNA) at Neutral
-
Moderna (MRNA) PT Raised to $24 at BofA Securities
-
Jefferies on Moderna (MRNA): '2026 Remains a Covid Story'
-
Moderna targets $1.6-2.0 billion revenue for 2025 amid product launches
-
Moderna files for approval of flu vaccine in four countries
-
Moderna Announces Global Regulatory Submissions for Its Investigational Seasonal Influenza Vaccine
-
Biotechnology: Here are Piper Sandler's Top Picks and Focus Names for 2026
-
CEPI invests $54.3 million in Moderna's H5 pandemic flu vaccine trial
-
Moderna to Present at the 44th Annual J.P. Morgan Healthcare Conference
-
EMA panel recommends approval of Moderna's new COVID vaccine mNEXSPIKE
-
EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's mNEXSPIKE (COVID-19 Vaccine, mRNA)
-
FDA may add black box warning to Covid-19 vaccines, CNN says
-
Jefferies Starts Moderna (MRNA) at Hold
-
FDA probe of alleged deaths tied to Covid shots includes adults
-
FDA Probe Of Alleged Deaths Tied To Covid Shots Includes Adults
-
Moderna (MRNA) on watch following comments at Piper
-
Piper Sandler on Moderna (MRNA): 'Project Revenue Growth to Resume'
-
Shares of vaccine makers drop after FDA memo flags reports of child deaths
-
Moderna (MRNA) Sentiment Can Improve with Prudent Near-Term Financial Execution - UBS
-
Needham Reiterates Hold Rating on Moderna (MRNA)
-
Moderna (MRNA) PT Raised to $18 at Leerink Partners
-
Moderna (MRNA) PT Lowered to $25 at RBC Capital
-
Moderna secures $1.5 billion credit facility from Ares Management
-
Moderna targets 10% revenue growth in 2026 with vaccine expansion plans
-
Moderna Analyst Day Highlights Pipeline Progress and Business Strategy Updates
-
Moderna Secures $1.5 Billion Five-Year Credit Facility from Ares Management
-
Moderna to move drug manufacturing to Massachusetts facility
-
Moderna Expands U.S. Manufacturing with Onshoring of Drug Product Capabilities
-
Moderna to Present at Upcoming Piper Sandler's 37th Annual Healthcare Conference on December 2, 2025
-
Bernstein Reiterates Market Perform Rating on Moderna (MRNA)
-
Stock market today: S&P 500 falls as job cuts stoke economic fears, tech stutters
-
Moderna revenue falls 45%, but still tops estimates
-
Moderna (MRNA) Tops Q3 EPS by $1.54
-
Moderna Reports Third Quarter 2025 Financial Results and Provides Business Updates
-
Moderna (MRNA) call put ratio 3.9 calls to 1 put into quarter results
-
Moderna doses first patient in multiple myeloma T-cell engager trial
-
Moderna Announces First Patient Dosed in Phase 1/2 Study of Investigational T-Cell Engager for Multiple Myeloma
-
Moderna (MRNA) call put ratio 4.2 calls to 1 put as share price up 17.4%
-
Moderna (MRNA) Trades Higher on Chatter
-
Moderna Named a Top Employer by Science for Eleventh Consecutive Year
-
Moderna to Host Investor Event - Analyst Day
-
Moderna (MRNA) PT Lowered to $40 at UBS
-
Moderna (MRNA) PT Lowered to $12 at Leerink Partners
-
After-hours movers: Tesla, IBM, Molina, Southwest Airlines, and more
